BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34326198)

  • 1. Activation of the
    Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
    Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
    Seo HK; Lee SJ; Kwon WA; Jeong KC
    Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines.
    Linke D; Donix L; Peitzsch C; Erb HHH; Dubrovska A; Pfeifer M; Thomas C; Fuessel S; Erdmann K
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
    Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
    PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
    Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
    Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
    Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
    J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
    Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
    Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERG induces taxane resistance in castration-resistant prostate cancer.
    Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
    Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
    Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
    Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Eskra JN; Schlicht MJ; Bosland MC
    Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
    Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.